Chlamydia trachomatis serology in women with and without ovarian cancer

Infect Dis Obstet Gynecol. 2008:2008:219672. doi: 10.1155/2008/219672. Epub 2008 Dec 18.

Abstract

Pelvic inflammation has been implicated in the genesis of ovarian cancer. We conducted serologic measurements of Chlamydia trachomatis antibodies as a surrogate marker of chlamydial pelvic inflammatory disease. Women with ovarian cancer (n = 521) and population-based controls (n = 766) were tested. IgG antibodies to serovar D of chlamydia elementary bodies (EBs) were detected using an ELISA assay. The odds of having ovarian cancer among women with the highest titers (>or=0.40 OD units) were 0.6 (95% CI 0.4-0.9). These data do not support our earlier finding of elevated titers for antibodies to C. trachomatis among women with ovarian cancer.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Bacterial / blood*
  • Case-Control Studies
  • Chlamydia Infections / blood
  • Chlamydia Infections / complications
  • Chlamydia Infections / immunology*
  • Chlamydia trachomatis / immunology*
  • Chlamydia trachomatis / isolation & purification
  • Confidence Intervals
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunoglobulin A / analysis
  • Immunoglobulin G / blood*
  • Logistic Models
  • Middle Aged
  • Odds Ratio
  • Ovarian Neoplasms / blood
  • Ovarian Neoplasms / complications
  • Ovarian Neoplasms / immunology*
  • Ovarian Neoplasms / microbiology
  • Pelvic Inflammatory Disease / complications
  • Pelvic Inflammatory Disease / microbiology
  • Risk Factors

Substances

  • Antibodies, Bacterial
  • Immunoglobulin A
  • Immunoglobulin G